Adenocarcinoma of the lung medical therapy: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) Created page with "__NOTOC__ {{Adenocarcinoma of the lung}} {{CMG}}; {{AE}} {{SC}} ==Overview== ==References== {{reflist|2}} {{WikiDoc Help Menu}} {{WikiDoc Sources}} Category:Disease C..." |
Shanshan Cen (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{SC}} | {{CMG}}; {{AE}} {{SC}} | ||
==Overview== | ==Overview== | ||
==Management== | |||
[[Targeted therapy]] is available for lung adenocarcinomas with certain mutations. [[Crizotinib]] is effective in tumors with fusions involving ALK or ROS1, whereas [[gefitinib]], [[erlotinib]], and [[afatinib]] are used in patients whose tumors have mutations in EGFR.<ref name=WCR20145.1/> | |||
==References== | ==References== | ||
Revision as of 18:34, 9 December 2015
|
Adenocarcinoma of the Lung Microchapters |
|
Differentiating Adenocarcinoma of the Lung from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Adenocarcinoma of the lung medical therapy On the Web |
|
American Roentgen Ray Society Images of Adenocarcinoma of the lung medical therapy |
|
Risk calculators and risk factors for Adenocarcinoma of the lung medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]
Overview
Management
Targeted therapy is available for lung adenocarcinomas with certain mutations. Crizotinib is effective in tumors with fusions involving ALK or ROS1, whereas gefitinib, erlotinib, and afatinib are used in patients whose tumors have mutations in EGFR.[1]
References
- ↑ Invalid
<ref>tag; no text was provided for refs namedWCR20145.1